clofibrate has been researched along with Proteinuria in 8 studies
angiokapsul: contains clofibrate & insoitolnicotinate
Proteinuria: The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The possibility that hyperlipidemia and an increase of mononuclear cells in the glomeruli could participate in the pathogenesis of minimal change glomerulopathy was evaluated in puromycin aminonucleoside (PAN) nephrosis in rats." | 7.69 | The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats. ( Hattori, T; Ito, M; Nagamatsu, T; Suzuki, Y, 1996) |
| " Clofibrate treatment reduced SBP by 26%±2% and proteinuria by 43%±9% in SHR but not in WKY rats." | 3.80 | PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats. ( Newaz, M; Yousefipour, Z, 2014) |
| "Inducing renal cytochrome P4504A (P4504A) activity with clofibrate prevents the development of hypertension in Dahl salt-sensitive (Dahl S) rats." | 3.70 | Effects of lipid-lowering agents in the Dahl salt-sensitive rat. ( Alonso-Galicia, M; Roman, RJ; Wilson, TW, 1998) |
| "The possibility that hyperlipidemia and an increase of mononuclear cells in the glomeruli could participate in the pathogenesis of minimal change glomerulopathy was evaluated in puromycin aminonucleoside (PAN) nephrosis in rats." | 3.69 | The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats. ( Hattori, T; Ito, M; Nagamatsu, T; Suzuki, Y, 1996) |
| " It will be important to establish the appropriate dosage of fibrates for treatment against kidney disease and to develop a novel PPARα activator that has a steady serum concentration regardless of kidney dysfunction." | 1.37 | Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration. ( Aoyama, T; Ehara, T; Gonzalez, FJ; Hashimoto, K; Higuchi, M; Hora, K; Kamijo, Y; Nakajima, T; Shigematsu, H; Takahashi, K, 2011) |
| "The early stage of diabetic nephropathy (DN) is linked to proteinuria." | 1.35 | Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy. ( Chang, HH; Inscho, EW; Luo, P; Seki, T; Wang, CY; Wang, MH; Zhang, J; Zhou, Y, 2009) |
| "Treatment with clofibrate significantly increased glomerular CYP450 4A expression." | 1.33 | Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier. ( McCarthy, ET; Sharma, M; Sharma, R, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yousefipour, Z | 1 |
| Newaz, M | 1 |
| Luo, P | 1 |
| Zhou, Y | 1 |
| Chang, HH | 1 |
| Zhang, J | 1 |
| Seki, T | 1 |
| Wang, CY | 1 |
| Inscho, EW | 1 |
| Wang, MH | 1 |
| Takahashi, K | 1 |
| Kamijo, Y | 1 |
| Hora, K | 1 |
| Hashimoto, K | 1 |
| Higuchi, M | 1 |
| Nakajima, T | 1 |
| Ehara, T | 1 |
| Shigematsu, H | 1 |
| Gonzalez, FJ | 1 |
| Aoyama, T | 1 |
| McCarthy, ET | 1 |
| Sharma, R | 1 |
| Sharma, M | 1 |
| Sankaralingam, S | 1 |
| Desai, KM | 1 |
| Glaeser, H | 1 |
| Kim, RB | 1 |
| Wilson, TW | 2 |
| Hattori, T | 1 |
| Nagamatsu, T | 1 |
| Ito, M | 1 |
| Suzuki, Y | 1 |
| Alonso-Galicia, M | 1 |
| Roman, RJ | 1 |
| Rush, P | 1 |
| Baron, M | 1 |
| Kapusta, M | 1 |
1 review available for clofibrate and Proteinuria
| Article | Year |
|---|---|
Clofibrate myopathy: a case report and a review of the literature.
Topics: Aged; Blood Sedimentation; Clofibrate; Creatine Kinase; Electromyography; Humans; Isoenzymes; Male; | 1986 |
7 other studies available for clofibrate and Proteinuria
| Article | Year |
|---|---|
PPARα ligand clofibrate ameliorates blood pressure and vascular reactivity in spontaneously hypertensive rats.
Topics: Animals; Antihypertensive Agents; Aorta; Biomarkers; Blood Pressure; Clofibrate; Disease Models, Ani | 2014 |
Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy.
Topics: 8,11,14-Eicosatrienoic Acid; Amino Acids; Animals; Clofibrate; Cytochrome P-450 CYP4A; Diabetes Mell | 2009 |
Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.
Topics: Animals; Clofibrate; Fatty Acids, Nonesterified; Female; Histocytochemistry; Hypolipidemic Agents; K | 2011 |
Protective effect of 20-hydroxyeicosatetraenoic acid (20-HETE) on glomerular protein permeability barrier.
Topics: Animals; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme System; Glomerular Filtration R | 2005 |
Inability to upregulate cytochrome P450 4A and 2C causes salt sensitivity in young Sprague-Dawley rats.
Topics: Aging; Animals; Anticholesteremic Agents; Blood Pressure; Clofibrate; Cytochrome P-450 CYP4A; Cytoch | 2006 |
The possible roles of hyperlipidemia and mononuclear cells in glomeruli in puromycin aminonucleoside nephrosis in rats.
Topics: Animals; Anticholesteremic Agents; Azathioprine; CD4-Positive T-Lymphocytes; Cholestyramine Resin; C | 1996 |
Effects of lipid-lowering agents in the Dahl salt-sensitive rat.
Topics: Animals; Blood Pressure; Cholesterol; Clofibrate; Cytochrome P-450 CYP4A; Cytochrome P-450 Enzyme Sy | 1998 |